지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2013.1
- 수록면
- 489 - 495 (7page)
이용수
초록· 키워드
오류제보하기
Objective : To evaluate the efficacy of temozolomide (TMZ) chemotherapy for recurrent anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA). Methods : A multi-center retrospective trial enrolled seventy-two patients with histologically proven AO/AOA who underwent TMZ chemotherapy for their recurrent tumors from 2006 to 2010. TMZ was administered orally (150 to 200 $mg/m^2/day$) for 5 days per 28 days until unacceptable toxicity occurred or tumor progression was observed. Results : TMZ chemotherapy cycles administered was median 5.3 (range, 1-41). The objective response rate was 24% including 8 cases (11%) of complete response and another 23 patients (32%) were remained as stable disease. Severe side effects (${\geq}$grade 3) occurred only in 9 patients (13%). Progression-free survival (PFS) of all patients was a median 8.0 months (95% confidence interval, 6.0-10.0). The time to recurrence of a year or after was a favorable prognostic factor for PFS (p<0.05). Overall survival (OS) was apparently differed by the patient's histology, as AOA patients survived a median OS of 18.0 months while AO patients did not reach median OS at median follow-up of 11.5 months (range 2.7-65 months). Good performance status of Eastern Cooperative Oncology Group 0 and 1 showed prolonged OS (p<0.01). Conclusion : For recurrent AO/AOA after surgery followed by radiation therapy, TMZ could be recommended as a salvage therapy at the estimated efficacy equal to procarbazine, lomustine, and vincristine (PCV) chemotherapy at first relapse. For patients previously treated with PCV, TMZ is a favorable therapeutic option as 2nd line salvage chemotherapy with an acceptable toxicity rate.
목차
등록된 정보가 없습니다.
참고문헌 (34)
참고문헌 신청
Balmaceda C / 2008 / Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas / Cancer 112:1139~1146
Brada M / 2001 / Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse / Ann Oncol 12:259~266
Brandes AA / 2006 / Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma : a prospective GICNO study / J Clin Oncol 24:4746~4753
Brandes AA / 2004 / Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study / Cancer 101:2079~2085
Cairncross G / 2006 / Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma : Intergroup Radiation Therapy Oncology Group Trial 9402 / J Clin Oncol 24:2707~2714
Brada M / 2001 / Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse / Ann Oncol 12:259~266
Brandes AA / 2006 / Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma : a prospective GICNO study / J Clin Oncol 24:4746~4753
Brandes AA / 2004 / Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study / Cancer 101:2079~2085
Cairncross G / 2006 / Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma : Intergroup Radiation Therapy Oncology Group Trial 9402 / J Clin Oncol 24:2707~2714
이 논문의 저자 정보
최근 본 자료
댓글(0)
0